Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Fulvestrant
Related studies linked through entity extraction aliases.
Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
- Status
- RECRUITING
- Phase
- PHASE2
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
- Status
- RECRUITING
- Phase
- PHASE2
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
- Status
- TERMINATED
- Phase
- PHASE2
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
- Status
- RECRUITING
- Phase
- PHASE1
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
- Status
- RECRUITING
- Phase
- PHASE3
Phase I Study of BEBT-209 in Women With Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE1
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants
- Status
- COMPLETED
- Phase
- PHASE2
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
- Status
- RECRUITING
- Phase
- PHASE2
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1